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Abstract  
Background. Detailed information on the profile of Brugada syndrome (BrS) patients 
presenting their first arrhythmic event (AE) after prophylactic implantation of a 
cardioverter defibrillator (ICD) is limited.  
 Objectives. 1) Compare the clinical, electrocardiographic, electrophysiologic and 
genetic profile of patients who exhibited their first documented AE as aborted 
cardiac arrest (CA) (group A) with those in whom the AE was documented after 
prophylactic ICD implantation (group B); 2) Characterize group B patients profile   
using the Class II indications for ICD implantation established by HRS/EHRA/APHRS 
Expert Consensus Statement in 2013.   
Methods. A survey of 21 centers from 10 Western and 3 Asian countries enabled 
collecting data from 628 BrS patients (group A, n=383; group B, n=245). 
Results. First AE occurred in group B patients 6 years later than in group A (46.2 + 
13.2 vs. 40.1 + 14.2, p<0.001). Group B patients had a higher incidence of family 
history of sudden cardiac death (SCD) and SCN5A mutations. Of the 245 group B 
patients, 183 (74.7%) complied with the HRS/EHRA/APHRS indications whereas the 
remaining 62 (25.3%) did not. 
Conclusion. BrS patients implanted appropriately with a prophylactic ICD exhibited 
their AE at a later age with a higher incidence of positive family history of SCD and 
SCN5A mutations compared to those presenting with an aborted CA. Only 75% of 
patients who suffered an AE after receiving a prophylactic ICD complied with the 
2013 Class II indications, suggesting efforts are still required for improving risk 
stratification.  
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                                                                 INTRODUCTION 
Brugada syndrome (BrS) is an inherited arrhythmic disorder that may result in 
sudden cardiac death (SCD) (1). Despite the considerable amount of publications on 
the topic since the first description of the syndrome by the Brugada brothers in 1992 
(2), the number of patients with documented arrhythmic events (AE) reported is 
relatively limited, in agreement with the low prevalence of the disease among 
patients with apparently normal hearts who exhibit SCD.  
Most prior studies have focused on patients with an aborted cardiac arrest (CA) as 
the presenting AE. The FINGER registry, published in 2010 (3), is a multicenter study 
that gathered 62 patients (out of a total of 1029 patients) from 4 European countries 
(France, Italy, Netherlands, Germany). The Pedro Brugada group (4), during a 20-year 
period, observed 25 patients who suffered an aborted CA. Similarly, the largest Asian 
series of aborted CA from Japan (5), South Korea (6) and Thailand (7) included 84, 77 
and 65 patients, respectively.  Based on these data a profile of BrS patients 
presenting with aborted CA has been drawn: male patients (>90%) in their fourth 
decade of life, most of them with spontaneous type 1-Brugada ECG who exhibited 
their AE without any warning symptoms. 
In contrast, detailed information regarding the profile of patients who exhibited their 
AE after prophylactic implantation of a cardioverter-defibrillator (ICD) is scarce and 
confined to 3 small series (8-10) comprising up to 14 patients (9). No previous study 
compared these patients with those presenting with aborted CA. Gaining insight into 
the profile of the patients who received a prophylactic ICD is important for 
determining whether  ICD indications in these patients complied with those 
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established in the HRS/EHRA/APHRS 2013 Expert Consensus Statement (11).  This 
could help in identifying other subgroups of patients who could draw benefit from 
prophylactic ICD implantation without sharing these consensual indications. 
We have recently organized a multicenter international survey on AE in BrS (the 
Survey on Arrhythmic events in BRUgada Syndrome, SABRUS) which collected data 
from a large cohort of 628 patients from multiple Western and Asian countries. The 
present study has 2 main objectives: 
1. Compare the clinical, electrocardiographic (ECG), electrophysiologic (EP) and 
genetic profile of patients who exhibited their first documented AE as aborted CA 
with those in whom the AE was documented after prophylactic ICD implantation. 
2. Analyze the profile of patients who exhibited their first AE after prophylactic ICD 
implantation based on the previously defined Class II indications for ICD implantation 
(11).   
 
                                                                     METHODS 
DATA SOURCE AND CENTER SELECTION.  
A systemic Medline search was conducted by one investigator (A.M) in order to locate the 
largest academic EP centers having experience in the diagnosis and management of AE’s 
in the setting of BrS. Meta-analyses and case reports were excluded. The centers were 
requested to state whether their data originated from a single or multiple institutions and 
to provide a list of participating institutions in order to prevent any duplication in data 
collection. 
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CENTER RECRUITMENT.  
Out of 25 centers contacted, 21 (84%) agreed to participate. Fourteen centers 
(66.6%) reported their sole experience and 7 (33.3%) collected the experience of 
multiple institutions. The French center that coordinated FINGER (3) provided data 
from 20 French institutions.  
A total of 628 patients were recruited from both Western (10 centers, 405 patients; 
64.5%) and Asian countries (3 centers, 223 patients; 35.5%) (Supplemental Table 1). 
The number of patients provided by each center ranged from 7 to 105 patients.  
The study was approved by the Institutional Committee on Human Research at the 
Tel Aviv Sourasky Medical Center. 
DATA ACQUISITION. 
Anonymous patient information was collected using a predefined questionnaire 
regarding the following: 1) mode of AE documentation (Group A or Group B, see 
below); 2) age at the time of the first AE; 3) gender; 4) ethnicity (Caucasian, Asian, 
other or unknown);  5) family history of SCD;  6) prior history of syncope ; 6) 
presence of spontaneous or drug-induced Brugada-ECG type 1; 7) inducibility of 
ventricular fibrillation (VF) at EP study (EPS); 8) results of genetic testing.  
In patients who had AE documented after receiving a prophylactic ICD but did not 
meet the  2013 guidelines for prophylactic ICD implantation (11), the relevant 
participating centers were asked to search for  QRS fragmentation (QRS-f) in leads 
V1-V3 (12), which was previously reported as a good predictor for AE (8,12).  
DEFINITIONS. 
Patient groups according to mode of AE documentation:  
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- Group A: Patients with documented aborted CA in whom the diagnosis of BrS 
was made a posteriori.  
- Group B: Patients with an a priori diagnosis of BrS in whom prophylactic ICD 
implantation was performed and an AE requiring appropriate ICD therapy 
was documented during follow-up. 
Arrhythmic events: AE was defined as any sustained ventricular tachyarrhythmia 
documented during initial aborted CA (group A) or requiring ICD therapy (group B).  
HRS/EHRA/APHRS Expert Consensus Statement (11): Current international 
guidelines recommend prophylactic ICD implantation in 2 groups of patients: a) 
those with spontaneous type 1 Brugada-ECG presenting with syncope judged likely 
to be caused by ventricular arrhythmias (Class IIa indication); b) those with a 
spontaneous or drug-induced type 1 ECG with inducible VF by programmed 
ventricular stimulation (Class IIb indication).                                                    
STATISTICAL ANALYSIS.  
Assumptions of normality of the age distributions amongst patient subgroups were 
assessed by Kolmogorov–Smirnov test and Q-Q plots. Differences between means of two 
groups of normally distributed ages were assessed using a Welch t-test. Differences 
between non-normally distributed ages were assessed using a Mann–Whitney U test for 
two groups, or a Kuraskal-Wallis test for three groups. Differences in proportions were 
assessed by a Chi-square test or a Fisher's exact test as appropriate. Statistical significance 
was defined as p<0.05. All calculations were performed using SPSS vs. 24 (IBM, Armonk, 
NY, USA).   
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RESULTS 
THE SURVEY GROUP  
Of the 628 patients enrolled in SABRUS, 575 (91.6%) were males and 53 (8.4%) 
females aged 0.27 to 84 (mean 42.5 ± 14.1) years old at the time of their first AE.  
The vast majority (96%) of patients were 16 to 70 years old. There were 355 (56.5%) 
Caucasians, 230 (36.6%) Asians and 43 (6.9%) who had other (2.1%) or unknown 
(4.8%) ethnic origin. Most patients (n=383, 61%) belonged to group A while the 
remaining 245 (39%) belonged to group B.  A family history of SCD was noted in 138 
(22%) patients, a prior history of syncope in 244 (38.9%) and a spontaneous type 1 
Brugada-ECG pattern in 412 (65.6%). VF was induced in 242 (64.9%) of the 373 
patients in whom EPS was performed. An SCN5A mutation was found in 131 (30.1%) 
of the 435 patients who underwent genetic testing. 
COMPARISON BETWEEN GROUP A AND GROUP B   
The clinical, ECG, EP and genetic findings of the patients in the 2 groups are 
presented in Table 1.  
Demographics. The male/female ratio was similar in group A (n=11.3) and group B 
(n=10.1) (p=0.679). Group B patients were ~ 6 years older than group A patients at 
time of first AE (46.2 + 13.2 vs. 40.1 + 14.2 years, p<0.001). The incidence of AE was 
higher before age 37 in group A (43.3%) vs. group B (24.9%). Since the survey 
recruited more patients from Western than Asian countries  there were more 
Caucasians  in both groups but the proportion of Asians with AE was greater in group 
A (41.5% vs. 29% in group B, p=0.001).  
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Clinical data. A family history of SCD was more frequently noted in group B (29%) 
compared with group A (17.5%) (p<0.001), as was a history of syncope (62% vs. 24%, 
p<0.001).                                    
ECG data. Spontaneous type 1 Brugada-ECG was observed in similar proportions of 
groups A and B patients (63.4% and 69%, respectively) (p=0.154).  
EP data. Group B patients underwent more EPS than group A (P<0.001) and had a 
greater proportion of positive results (73.2% vs 55.9% in group A, p<0.001).                                                                                                                     
Genetic data. A similar proportion of patients in both groups underwent genetic 
testing (71.5% and 65.7% for groups A and B, respectively). An SCN5A mutation was 
more frequently observed in group B (37.9%) than in group A (25.5%) (p=0.007). 
Among patients with a family history of SCD, the proportion of SCN5A mutation was 
slightly higher for group B patients (42.9% vs. 36.1% in group A), but the difference 
did not reach statistical significance (p=0.452).  
DETAILED CHARACTERISTICS OF GROUP B PATIENTS. 
Group B patients were divided into 3 subgroups according to their adherence with 
the Class II indications for ICD (11): a) Group B1 (Class IIa indication): 106 (43.3%) 
patients; b) Group B2 (Class IIb indication): 77 (31.4%) patients; c) Group B3 (neither 
Class IIa nor Class IIb indications): 62 (25.3%) patients. The clinical, ECG, EP and 
genetic findings of group B patients are presented in Table 2.  
Although the proportion of females in group B3 was greater than in the other 2 
groups, this difference was not statistically significant. However, a family history of 
SCD was more frequently noted in group B2 (39%) and group B3 (30.6%) as 
compared to group B1 (20.8%) (p<0.01 and p<0.05, respectively). No significant 
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difference was observed between the 3 subgroups in regard to age at first AE, ethnic 
origin and the presence of SCN5A mutation.  
As expected by group definition criteria, prior syncope and spontaneous type 1 
Brugada-ECG predominated in group B1. Similarly, VF inducibility predominated in 
group B2 and was absent in group B3. 
CHARACTERISTICS OF GROUP B3.  
The clinical, ECG, EP and genetic findings of the 62 group B3 patients are presented 
in Table 3. In 32 (51.6%) patients (group B3a) EPS was performed but yielded 
negative results while in the remaining 30 (48.4%) patients (group B3b) EPS was not 
performed. Table 4 provides a flowchart of the detailed patient characteristics of 
these 2 subgroups. 
The only striking difference between these 2 subgroups of patients was the higher 
proportion of females in the non-inducible group (18.8% vs. 6.7%) but this difference 
did not reach statistical significance (p=0.258). QRS-f was found in ~ 30% of patients 
of either subgroup (31% and 30%, respectively) irrespectively of the presence of 
spontaneous type 1 Brugada-ECG.  
When dividing group B into 3 almost equal subgroups according to the date of ICD 
implantation, there was a rise over the years of the proportion of patients who 
received an ICD without complying with conventional guidelines (Supplemental 
Table 2). There was no difference in clinical characteristics of B3 patients (age, 
gender, ethnicity, familial history of SCD, prior syncope, ECG type) between the 3 
periods.    
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We could not identify a single parameter uniting group B3 patients (besides the 
definition of not having a conventional class II indication) using a logistic regression 
multivariate model (Supplemental Table 3).                                                                
                                                                    
                                                                 DISCUSSION 
The strength of SABRUS comes from its large cohort of BrS patients who suffered 
their first documented AE either at the time of aborted CA or after a prophylactic ICD 
implantation. 
MAIN SURVEY RESULTS. 
The results gathered from these 628 BrS patients demonstrated 2 main findings: 1. 
Group B patients exhibited a later occurrence of AE and a higher incidence of family 
history of SCD and SCN5A mutations than group A; 2. Although ~ 75% of group B 
patients complied with the Class IIa and IIb indications for primary ICD implantation 
established by the Expert Consensus Statement, the remaining 25% patients did not.  
COMPARISON BETWEEN GROUP A AND GROUP B. 
The profile of group A patients from SABRUS was similar to previously reported 
largest studies of CA survivors (3,4,5-7). However, besides the similarity in the male 
predominance (>90%) and the presence of spontaneous type 1 Brugada-ECG in 
about two thirds of patients from both groups, there were marked differences 
between the 2 groups in regard to the age at onset of AE, patient ethnicity, family 
history of SCD, prior history of syncope, arrhythmia inducibility and genetic findings. 
Age at onset of AE.  Priori et al. noted that patients with first AE documented after 
prophylactic ICD implantation (8) were 14 years older than those presenting with aborted 
CA (13)  (47 + 12 vs. 33 + 13 years, respectively).  In SABRUS the initial AE occurred at a 
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mean age of 40.1 and 46.2 years in groups A and B, respectively, i.e ~ 6 years later in 
group B. This difference was attested by our data showing a higher incidence of AE in 
group A patients aged < 37 years (43.2%) than in group B (24.9%). There are 2 possible 
explanations for this marked late occurrence of AE in group B patients:  a) the arrhythmias 
in group A patients could have a more malignant character striking the patient at a 
younger age; b) the lack of effective ECG screening and arrhythmic risk assessment in the 
younger patient group contrasting with a better stratification in the older group.  
Ethnicity. In SABRUS a greater proportion of Asian patients were observed in group A.  
Interestingly, in FINGER (3) (the largest European BrS series), the CA survivors group 
included only 62 patients while the syncope group and the asymptomatic group included 
313 and 654 patients, respectively. In contrast, in the largest Asian BrS series from 
Thailand (7) (that were not included in SABRUS), 65 patients presented with aborted CA, 
14 with unexplained syncope and 11 were asymptomatic. This difference in the mode of 
AE presentation between Caucasians and Asians could suggest a more malignant 
presentation of AE in Asians or a less effective screening program in Asian countries.  
Family history of SCD.  A higher incidence of family history of SCD was found in group B 
(29%) compared with group A patients (17.5%). It is noteworthy that in 3 large series of 
BrS patients (3,4,8) and in the prospective study of Sarkozy et al. (14), the incidence of 
family history of SCD was highest in asymptomatic patients (30-58.7%), lowest in CA 
survivors (10-40%), and intermediate (20-51%) in patients presenting with syncope. These 
results cannot be directly compared to those of our survey since only a small proportion 
of the patients in the above mentioned studies exhibited AE during follow-up as 
compared to our group B patients who all exhibited AE. The reason for the concordant 
findings of a higher incidence of a family history of SCD in patients who did not present 
 
 
15 
with aborted CA has not been previously addressed. One possible explanation could be 
that a substantial number of these patients were identified after routine familial screening 
following the SCD of a family member that notably increased their family history of SCD 
rate as compared to patients with aborted CA.  
Prior history of syncope. Priori and coworkers previously reported that a history of 
syncope was more frequently noted in patients with AE that was documented after 
prophylactic ICD implantation (50%) (3) than in CA survivors (23.5%) (13). Similar 
results were found in SABRUS with figures of 62% and 24%, respectively.  Such 
differences could be due to the fact that a previous syncope was one of the inclusion 
criteria in the B1 subgroup fulfilling Class IIa indications.    
Arrhythmia inducibility. The results of SABRUS also showed a higher proportion of 
patients with inducible VF in group B (73.2% vs. 55.9% in group A). Such results are 
consistent with the fact that arrhythmia inducibility was the inclusion criterion in the 
B2 subgroup fulfilling Class IIb indications. In addition it is possible that the 
stimulation protocols used in group B patients were more aggressive (in order to 
minimize false negative results) than in group A (where EPS was mainly performed 
for academic purpose since the EP results were unlikely to affect patient 
management with ICD).    
Genetic findings. The latest meta-analysis by Wu et al. (15) indicated that an SCN5A 
gene mutation did not increase the risk of future cardiac events. In contrast a recent 
Japanese study showed that SCN5A mutation was a significant predictor of cardiac 
events in BrS probands (16). In SABRUS, an SCN5A mutation was more frequently 
observed in group B (37.9%) than in group A (25.5%) (p=0.007). The fact that a 
greater proportion of group B patients had a family history of SCD (29% vs. 17.5% in 
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group A, p<0.001) and that a greater (albeit non-significant) incidence of SCN5A 
mutation was found among those patients with a family history of SCD in group B 
patients could explain our findings.    
PROFILE OF GROUP B PATIENTS. 
In addition to group B1 and group B2 who fulfilled Class IIa and IIb indications, 
respectively, the survey showed another sizeable group (B3, 25.3% of patients) who 
did not fulfill these indications. Besides a higher incidence of a family history of SCD 
in group B2 and group B3 as compared to group B1 as well as intergroup differences 
due to group criteria definitions, there were no significant differences between these 
3 groups in regard to patient age at time of AE, ethnic origin, and the presence of 
SCN5A mutation.  
The fact that group B1 comprised more patients than group B2 is consistent with the 
results of the Multicenter Japanese study on the long-term prognosis of BrS patients 
with no previous CA, based on Class II indications for ICD implantation (17). In this 
latter study the incidence of AE during > 5 years follow-up was much higher in 
patients who fulfilled Class IIa indications (12%) than in those who fulfilled Class IIb 
indications (3%, p = 0.01). Such results validate the classification adopted in the 
Expert Consensus Statement (11) establishing that patients with Class IIa indication 
exhibit an increased risk as compared to those with Class IIb indication.  
CHARACTERISTICS OF GROUP B3. 
For the first time SABRUS presented in a large cohort of patients that  AE can occur 
after prophylactic ICD implantation in a significant percentage of patients (25.3%) 
who do not fulfill Class II indications. This group comprised 2 subgroups of similar 
size: one in whom EPS did not induce arrhythmias (n=32) and the second in whom 
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EPS was not performed (n=30). Interestingly the proportion of Caucasians and Asians 
in group B3 among group B patients was similar (25.3% and 25%, respectively). 
Analysis of the PRELUDE results (8) showed that out of 14 patients without previous 
CA who exhibited an AE (after prophylactic ICD implantation in 13 patients) 5 (36%) 
did not fulfill Class IIa or Class IIb indications. The Pedro Brugada group (9) also 
reported a group of 6 non-inducible patients (2 asymptomatic and 4 with prior 
syncope) who did not comply with Class II indications and presented AE during 
follow-up after prophylactic ICD implantation. 
Taking into account that arrhythmia inducibility is a critical factor for deciding upon 
prophylactic ICD implantation in BrS, aggressiveness of the protocol of programmed 
ventricular stimulation (PVS) used is of paramount importance.  In this regard, it is 
possible that the non-aggressive PVS protocol in the Pedro Brugada’s laboratory 
(9,18) could have played a role in the non inducibility of the arrhythmias in their 
patients (9). However, a small annual incidence of AE (0.23 – 0.78) has also been 
observed in patients who had no arrhythmias induced using “standard” PVS 
protocols (19). In addition, in SABRUS the non-inducible group (B3a) included a 
relative high proportion of females who have been shown to exhibit a lower 
inducibility rate of VF than males (20). Thus it is tempting to speculate that a more 
aggressive PVS protocol (18,21) could have resulted in a higher inducibility rate of 
arrhythmias, enabling inclusion of the inducible patients in the B2 group.  
The issue of patients in whom EPS was not performed and who received a 
prophylactic ICD not based on Class II indications, just to exhibit an AE during follow-
up has not been previously addressed.  Our data showed that the proportion of such 
patients has been growing over the years, probably due to the increasing doubts of 
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the EP community concerning the role of EPS in predicting arrhythmic risk in BrS. 
This subgroup of patients represented a non-negligible fraction of group B patients 
in SABRUS (12.2%). They shared similar clinical and ECG characteristics as the 
subgroup of patients with negative EPS (B3a). However it is likely that performance 
of EPS in this subgroup of patients would have yielded positive results in some of 
them, thus enabling their inclusion in group B2. 
Careful analysis of the B3 group characteristics failed to identify any obvious clinical 
or laboratory criteria that could raise suspicion of the very high arrhythmic risk of 
these patients.  In this regard it is noteworthy that the total number of patients 
unnecessarily treated with a prophylactic ICD based on such non-conventional 
indications was unknown from our survey results.  
CLINICAL IMPLICATIONS. 
The results of SABRUS emphasize the need for improving diagnosis and screening of 
young patients with BrS in order to decrease the relatively high AE rate in this 
patient population. In addition they do confirm the validity of Class II indications 
established by the Expert Committee (11) in 75% of the SABRUS patients without 
previous CA.  However the fact that the remaining 25% of patients exhibited AE in 
spite the fact they did not fulfill the conditions justifying this implantation based on 
these guidelines, is of a great concern. A strict application of the guidelines 
recommendations in these patients would have discarded ICD implantation and 
could have had a fatal outcome. On the other hand widening the indications for 
prophylactic ICD implantation in BrS based on the data provided by SABRUS in group 
B3 is likely to result in unnecessary ICD implantations in a considerable amount of 
patients. Our data suggest that major efforts should be made to assign these 
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patients to group B1 or B2: a) patients experiencing syncope should be thoroughly 
evaluated for differentiating neurally-mediated syncope from suspected arrhythmic 
syncope (22); b) when a spontaneous type 1 Brugada-ECG is not initially 
documented, close ECG monitoring should be instituted in order to detect its 
occurrence during follow-up especially in those patients who initially presented with 
syncope; c) patients who initially refused to undergo EPS for risk stratification should 
be encouraged to do so; d) repetition of double extrastimulation at the shortest 
coupling intervals (18) might be considered in order to increase sensitivity of the PVS 
protocol without  affecting its specificity. However, one should recognize that 
despite these efforts it might be that the patient’s clinical and familial history as well 
as the patient’s and the family’s wishes will lead to ICD implantation that will prove 
justified despite the lack of strict adherence to Class II indications. We believe that 
this possibility should be kept to the minimum. 
STUDY LIMITATIONS.  
The survey is not a multicenter prospective study but rather a retrospective 
cumulative analysis of results from the largest EP centers which have experience 
with BrS.  Despite our repeated efforts, we could not recruit more centers from 
other Asian countries (especially Thailand). The definitions of family history of SCD 
and syncope were left to the discretion of the participating centers. The information 
requested from the participant centers about the Brugada-ECG type only dealt with 
the patient’s ECG pattern at ICD implantation; we cannot exclude that some of the 
patients with initial drug-induced type 1 Brugada ECG developed it later 
spontaneously. The protocol of PVS most probably varied among the survey centers, 
however the immense majority of centers used up to 3 extrastimuli from 1-2 right 
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ventricular sites. There was no information about the patients’ or physicians’ 
involvement in the decision to implant a prophylactic ICD in those patients who did 
not fulfill Class II indications.  
CONCLUSIONS. 
For the first time SABRUS describes the profile of patients with BrS who developed 
an AE after prophylactic ICD implantation in a large patient population. The profile of 
these patients differs from those of CA survivors.  Although comprising mainly 
patients who complied with Class II indications for ICD established by the 
HRS/EHRA/APHRS Expert Committee, this group of patients also included a non-
negligible proportion of patients who did not comply with these indications. Major 
efforts are still necessary for improving arrhythmic risk stratification in BrS.
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TABLE 1: Comparison between group A and group B 
Group A Group B P value
(n=383) (n=245)
Gender
Male 352 (91.9) 223 (91)
Female 31 (8.1) 22 (9.0)
Patient age at AE
All patients (years) 40.1 ± 14.2 46.2 ± 13.2 <0.001
< 16 15 (3.9) 4 (1.6)
16-70 365 (95.3) 238 (97.1)
>70 3  (0.8) 3 (1.2)
Ethnicity
Caucasian 195 (50.9) 160 (65.3)
Asian 159 (41.5) 71 (29)
Other 29 (7.5) 14 (5.7)
Family history of SCD
Yes 67 (17.5) 71 (29)
No 278 (72.6) 147 (60)
Unknown 38 (9.9) 27 (11)
Prior history of syncope
Yes 92(24) 152 (62)
No 291(76) 93 (38)
Spontaneous type 1 ECG
Yes 243 (63.4) 169 (69)
No 140 (36.6) 76 (31)
VF inducibility
 EPS performed 179 (46.7) 194 (79) <0.001
Yes 100 (55.9) 142 (73.2)
No 79 (44.1) 52 (26.8)
Presence of SCN5A  mutation
Testing done 274 (71.5) 161 (65.7) 0.123
Yes 70 (25.5) 61 (37.9)
No 204 (74.5) 100 (62.1) <0.01
0.679
<0.001 
0.276
<0.01
<0.001
<0.001
0.154
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TABLE 2. Detailed characteristics of group B 
 
B1 B2 B3
Class II a Class II b No Class IIa or IIb P-value
Syncope + Type 1 ECG Inducible VF
No of patients 106 (43.3) 77 (31.4) 62 (25.3)
Gender
Male 97 (91.5) 72 (93.5) 54 (87.1)
Female 9 (8.5) 5 (6.5) 8 (12.9)
M/F ratio 10.8 14.4 6.7
Age
All patients 45 ± 12.6 48 ± 12.5 46.1 ± 14.8 0.294
< 16 1 (0.9) 0 (0) 3 (4.8)
16-70 105 (99) 75 (97.4) 58 (93.5)
>70 0 (0) 2 (2.6) 1 (1.6)
Ethnicity
Caucasian 66 (62.3) 54 (70.1) 40 (64.5)
Asian 36 (34) 17 (22.1) 18 (29)
Others 4 (3.8) 6 (7.8) 4 (6.5)
Family history of SCD
Yes 22 (20.8) 30 (39) 19 (30.6)
No 76 (71.7) 40 (51.9) 31 (50)
Unknown 8 (7.5) 7 (9.1) 12 (19.4)
Prior syncope
Yes 106 (100) 20 (26) 26 (41.9)
No 0 (0) 57 (74) 36 (58.1)
Type 1 ECG
Yes 106 (100) 37 (48.1) 26 (41.9)
No 0 (0) 40 (51.9) 36 (58.1)
VF inducibility
 EPS performed 85 (80.2) 77 (100) 32 (51.6) <0.001 
Yes 65 (76.5) 77 (100) 0 (0)
No 20 (23.5) 0 (0) 32 (100)
SCN5A mutation 
Testing done 65 (61.3) 53 (68.8) 43 (69.4) 0.448
Yes 25 (38.5) 15 (28.3) 21 (48.8)
No 40 (61.5) 38 (71.7) 22 (51.2)
<0.05*,β
 
<0.001 ‡,∑,µ
0.118
0.410
<0.05§,α 

0.409
<0.001‡,β
<0.001‡,∑
§ p<0.05 B3 vs B1, α p<0.05 B3 vs B2, * p<0.01 B1 vs B2, β p<0.05 B1 vs B3, ‡ p<0.001 B1 vs 
B2, ∑ p<0.001 B1 vs B3, µ p<0.001 B2 vs B3. 
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TABLE 3. Comparison between B3 subgroups 
B3a B3b
No Class IIa or IIb No Class IIa or IIb
Non inducible VF EPS not performed 
No of patients 32 (51.6) 30 (48.4)
Gender
Male 26 (81.3) 28 (93.9)
Female 6 (18.8) 2 (6.7)
Age
All patients 46.9 ± 16 45.2 ± 13.7 0.651
< 16 years 2 (6.3) 1 (3.3)
16-70 29 (90.6) 29 (96.7)
>70 years 1 (3.1) 0 (0)
Ethnicity
Caucasian 24 (77.4) 16 (59.3)
Asian 7 (22.6) 11 (40.7)
Others 0 (0) 0 (0)
Family history of SCD
Yes 11 (34.4) 8 (26.7)
No 17 (53.1) 14 (46.7)
Unknown 4 (12.5) 8 (26.7)
Prior syncope
Yes 14 (43.8) 12 (40)
No 18 (56.3) 18 (60)
Type 1 ECG
Yes 14 (43.8) 12 (40)
No 18 (56.3) 18 (60)
VF inducibility
EPS performed 32 (51.6) 0 (0) <0.001
Yes 0 (0) 0 (0)
No 32 (100) 0 (0)
SCN5A  mutation
Testing done 23 (71.9) 20 (66.7) 0.657
Yes 11 (47.8) 10 (50)
No 12 (52.2) 10 (50)
P value
N/A
0.887
0.258
1.00
0.136
0.833
0.765
0.765
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TABLE 4.  Flow chart of ICD indications in subgroup B3 
 
EPS 
Symptoms       Asymptomatic                                Syncope
ECG         ST1 +           ST1 -         ST1 +         ST1 -
    14 (77.8%)       4 (22.2%)          0 (0%)      14 (100%)
M/F                13/1
Fragmented  QRS     Yes
No 
N.A
Family history SCD Yes
No
N.A
SCN5A
EPS: No Inducible Arrhythmias  n=32
No Syncope + Spontaneous Type 1 ECG
9
1
4
9
1
1
1
2
7
2
1
1
2
0
0
0
4
0
6
7
1
    18 (56.3%) 14 (43.8%)
0
0
5
5 2 0 4
4/0 0/0 9/5
 
EPS 
Symptoms
ECG         ST1 +
   12 (66.7%)
M/F
Fragmented QRS     Yes
No 
N.A
Family history SCD Yes
No
N.A
SCN5A
7
5 1 0
EPS: Not Performed n=30
No Syncope + Spontaneous Type 1 ECG
4 2 0 2
3
3 3 0
 ST1 + 
0 (0%) 12 (100.0%)
      Asymptomatic Syncope
   18 (60.0%) 12 (40.0%)
0
0
0
5
3
4
0
9
3
5 3 0 2
3
0
3
12/0 4/2 0/0 12/0
ST1 - ST1 -
6 (33.3%)
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SUPPLEMENTAL TABLE 1: List of participating centers 
Country Center No Patients (%)
France Multiple 130 (20.5)
Japan Multiple 119 (18.9)
Italy Multiple 84(13.5)
South Korea Multiple 79(12.6)
Belgium Multiple 48(7.6)
Netherlands Single 33(5.3)
Israel Multiple 31(5.1)
Spain Multiple 25(4)
China Multiple 25(4)
UK Single 20(3.2)
Germany Single 17(2.7)
Denmark Single 10(1.6)
Canada Single 7(1.1)  
SUPPLEMENTAL TABLE 2: Proportion of B1, B2 and B3 patients over time. 
Periods
Group B1
Group B2 
Group B3
        B3a
       B3b
14 (17.3)
16/05/2007- 04/12/2015
36 (44.4)
01/09/1987- 19/06/2003
106 (43.3)
77 (31.4)
62 (25.3) 
32 (13.1)
4 (4.9) 11 (13.4) 15 (18.3)
34 (41.5)
10 (12.3) 9 (11) 13 (15.8)
1st third (n=81) 2nd third (n=82) 3rd third (n=82)
31 (38.3) 26 (31.7)
All group B (n=245)
20 (24.4) 28 (34.1)
20 (24.4)
36 (43.9)
25/06/2003 - 04/05/2007
30 (12.2)  
 
 
SUPPLEMENTAL TABLE 3: Logistic regression analysis 
Parameter OR [95% CI] p-value 
Gender 0.72 [6.29-0.173] 0.173 
Ethnicity 0.33 [2.3-0.774] 0.774 
Family history of SCD 0.38 [1.91-0.706] 0.706 
SCN5A mutation 0.72 [3.4-0.256] 0.256 
 
 
